Astrazeneca Pharma firms up after announcing investment in India

Capital Market 

Pharma rose 3.28% to Rs 1,027.15 at 9:42 IST on after parent, AstraZeneca, announced its decision of further investing $90 million over the next 5 years in

The announcement was made after market hours yesterday, 17 April 2018.

On the BSE, 695 shares were traded in the counter so far compared with average daily volumes of 695 shares in the past two weeks. The stock had hit a high of Rs 1,045.50 and a low of Rs 1,008.80 so far during the day. The stock hit a 52-week high of Rs 1,278 on 7 November 2017. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

Leading global company announced its decision of further investing $90 million over the next 5 years in The announcement was made following the signature of the bilateral innovation partnership for a sustainable future between and

This investment commitment will span across AstraZeneca's diverse footprint in with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of in

Pharma reported net loss of Rs 10.35 crore in Q3 December 2017 as against net profit of Rs 16.21 crore in Q3 December 2016. Net sales declined 14.47% to Rs 128.54 crore in Q3 December 2017 over Q3 December 2016.

Pharma is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in such as diabetes, heart disease, cancer, &

As on 31 December 2018, Pharmaceuticals AB held 75% stake in Pharma

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, April 18 2018. 09:43 IST